Study guide

9.2 Corticosteroids, Sustained-Release Implants & AREDS Supplements

IJCAHPO Certified Retina Technician CRT

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview: Current CRT Requirements & Blueprint

Exam Overview: Current Requirements, Scope & Study Plan

2 Chapter 1: History Taking, Triage & Clinical Documentation

1.1 Comprehensive Ophthalmic & Medical History for Retina Patients 1.2 Telephone Triage, Urgent Symptoms & Emergency Scheduling 1.3 Scribing, Electronic Health Records & Retinal Billing Codes

3 Chapter 2: Visual Assessment & Low Vision Rehabilitation

2.1 Standardized Visual Acuity Testing & Optotypes 2.2 Sub-Chart Acuity Protocols: CF, HM, LP, and NLP 2.3 Low Vision Definitions, Optical Devices & Patient Counseling

4 Chapter 3: Pupil Assessment & Visual Field Testing

3.1 Pupillary Examination & Relative Afferent Pupillary Defect 3.2 Confrontation Fields & Automated Perimetry in Retina 3.3 Amsler Grid Testing & Metamorphopsia Monitoring

5 Chapter 4: Tonometry & Ocular Motility

4.1 Goldmann Applanation & Handheld Tonometry Techniques 4.2 Tonometer Disinfection, Calibration & Post-Procedure IOP Monitoring 4.3 Ocular Motility Assessment, Strabismus & Alignment Testing

6 Chapter 5: Diagnostic Ophthalmic Ultrasound

5.1 Ophthalmic B-Scan Echography for Posterior Segment Pathology 5.2 Standardized A-Scan Echography & Optical Biometry

7 Chapter 6: Slit Lamp, Electrophysiology & Supplemental Testing

6.1 Slit Lamp Biomicroscopy, Illumination & Fundus Lenses 6.2 Color Vision Assessment & Hertel Exophthalmometry 6.3 Ophthalmic Electrophysiology: ERG, VEP, and EOG

8 Chapter 7: Ophthalmic Microbiology & Infection Control

7.1 Ocular Pathogens & Routes of Disease Transmission 7.2 Clinical Asepsis, Universal Precautions & Vitreous Specimen Collection

9 Chapter 8: General Retinal Pharmacology & Therapeutics

8.1 Ocular Drug Delivery Methods & Routes of Administration 8.2 Mydriatics, Cycloplegics & Diagnostic Ophthalmic Dyes 8.3 Anesthetics, Glaucoma Agents & Prescription Verification

10 Chapter 9: Anti-VEGF Therapies, Steroids & Retinal Toxicity

9.1 Anti-VEGF Agents & Neovascular Retinal Diseases 9.2 Corticosteroids, Sustained-Release Implants & AREDS Supplements 9.3 Systemic Medication Retinal Toxicity & Plaquenil Screening

11 Chapter 10: Surgical Assisting & Intravitreal Procedures

10.1 Intravitreal Injection Protocol, Antisepsis & Complication Checks 10.2 Retinal Laser Therapy Modalities & Laser Safety Protocols 10.3 Surgical Instrument Handling, Tray Setup & Sterilization

12 Chapter 11: Patient Services, Education & Clinical Care

11.1 Patient Education, Chronic Disease Counseling & Treatment Adherence 11.2 Special Needs Accommodations, Patient Diversity & Interpersonal Skills 11.3 Ophthalmic Emergencies, First Aid & Clinical Care Coordination 11.4 Clinic Operations, Research Support, Forms & Referrals

13 Chapter 12: General Ocular Anatomy & Retinal Physiology

12.1 Ocular Anatomy, Orbit & Posterior Segment Architecture 12.2 Ten Retinal Layers, Photoreceptors & Macular Anatomy 12.3 Ocular Blood Supply, Microcirculation & Vitreoretinal Interface 12.4 Body Systems, Ocular Adnexa & Medical Terminology

14 Chapter 13: Retinal Pathology & Systemic Disease Manifestations

13.1 Age-Related Macular Degeneration & Retinal Vascular Occlusions 13.2 Diabetic Retinopathy & Systemic Diseases Affecting the Retina 13.3 Peripheral Retinal Degenerations, Tears & Detachments

15 Chapter 14: Ophthalmic Optics & Lensometry

14.1 Principles of Ophthalmic Optics & Refraction 14.2 Manual & Automated Lensometry Techniques

16 Chapter 15: Fundus Photography & Ophthalmic Angiography

15.1 Fundus Photography Techniques & Fundus Autofluorescence 15.2 Fluorescein Angiography Principles, Phases & Image Interpretation 15.3 Indocyanine Green Angiography & Angiographic Complication Management

17 Chapter 16: Optical Coherence Tomography (OCT & OCT-A)

16.1 OCT Principles, Scan Acquisition & Artifact Recognition 16.2 Structural OCT Interpretation: Retinal Fluid & Biomarkers 16.3 Optical Coherence Tomography Angiography (OCT-A) Principles & Flow

18 Chapter 17: Equipment Maintenance, Ethics & Regulatory Compliance

17.1 Equipment Maintenance, Calibration Schedules & Clinic Safety 17.2 Medical Ethics, Scope of Practice & Informed Consent 17.3 Patient Privacy, HIPAA Standards & Hazardous Waste Disposal

9.2 Corticosteroids, Sustained-Release Implants & AREDS Supplements

Key Takeaways Explain This Topic AI

Corticosteroid selection, dose, implant, and follow-up are clinician decisions; monitor the ordered vision, pressure, inflammation, lens, and imaging measures.

A quiet eye with visible steroid crystals may represent pseudoendophthalmitis, but pain alone cannot reliably separate sterile material, inflammation, and infection.

AREDS or AREDS2 reduces progression from intermediate to advanced AMD by about 25 percent in the studied risk groups and does not prevent AMD onset or restore lost vision.

Current and former smokers should avoid beta-carotene-containing AREDS and use the clinician-recommended AREDS2 formulation because beta-carotene increased lung-cancer risk.

Copper was included with zinc in the study formulations to reduce zinc-related copper deficiency; patients should review supplements and interactions with a clinician.

Last updated: September 2026

Corticosteroids, Implants, and AREDS2 Supplements

This topic combines two different forms of care: prescription intraocular corticosteroids and oral nutritional supplements studied for age-related macular degeneration. Neither is a cure-all, and both require attention to the actual product and patient.

Retinal corticosteroid therapy

Corticosteroids reduce inflammatory signaling and vascular permeability. Retina specialists may use intravitreal triamcinolone or sustained-release dexamethasone or fluocinolone products for selected edema or inflammatory conditions. Product indications, duration, contraindications, injection or implant technique, and follow-up differ.

Important surveillance findings include:

  • intraocular-pressure elevation or a new need for pressure-lowering therapy;
  • cataract progression in a phakic eye;
  • pain, redness, photophobia, inflammation, or declining vision;
  • implant position and migration risk in eyes with altered capsules or anatomy;
  • OCT response and recurrence of edema;

infection or a sterile inflammatory reaction.

The technician records the exact product, eye, date, lot when required, prior response, pressure trend, lens status, and current symptoms. Do not generalize a release duration or reinjection interval from one implant to another.

Triamcinolone crystals can sometimes appear as white material in the vitreous or anterior chamber and mimic a hypopyon. A quiet, painless presentation may favor pseudoendophthalmitis, but symptoms and timing overlap with infection and sterile inflammation. Any unexpected post-injection vision change, pain, redness, or white material is promptly escalated for examination. The technician does not reassure solely from appearance.

AREDS and AREDS2 evidence

The National Eye Institute reports that AREDS or AREDS2 supplements reduce the risk of progression from intermediate to advanced AMD by about 25 percent in the populations studied. They do not prevent AMD from starting, do not treat cataract, and do not restore vision already lost to atrophy or scarring.

The AREDS2 formulation replaced beta-carotene with lutein and zeaxanthin. Current and former smokers should avoid the older beta-carotene formulation because trials found increased lung-cancer risk. The commonly described AREDS2 study formulation contains vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin, but commercial labels vary. The patient should compare the actual ingredient list with the clinician's recommendation rather than rely on the words eye vitamin.

Copper was included in formulations containing zinc to reduce the risk of zinc-related copper deficiency. This does not mean every patient should independently add copper or zinc. High-dose supplements can interact with medications, affect laboratory results, or be inappropriate for some conditions. The clinician reviews smoking history, AMD category, diet, comorbidities, and other supplements.

Counseling boundaries

A useful explanation is:

Who may benefit: typically patients with intermediate AMD or advanced AMD in one eye, as determined by the eye-care clinician.

What benefit means: lower probability of progression, not guaranteed prevention and not visual recovery.

What remains necessary: smoking cessation support, monitoring, home symptom awareness, and scheduled examination.

What to verify: formulation, expiration, dose, other vitamins, medications, and prior adverse effects.

New distortion, a central dark spot, or sudden vision change is not managed by taking extra supplement tablets. It requires prompt contact with the eye-care team.

Comparison

Item Purpose Major safety focus

Intravitreal corticosteroid Reduce selected inflammation or edema IOP, cataract, infection/inflammation, anatomy, product label

Sustained-release implant Longer local steroid exposure Implant-specific duration, pressure, lens, migration risk

AREDS2 supplement Reduce AMD progression risk in studied groups Correct indication, no beta-carotene for smokers/former smokers, interactions

Keep drug therapy, imaging response, and nutrition counseling clearly separated in documentation.

Monitoring and counseling boundaries

Before an ordered steroid procedure, verify glaucoma history, prior steroid response, lens status, infection concerns, current medications, and the correct product and route. Follow-up commonly includes pressure, inflammation, lens status, and structural or functional response, but the clinician sets timing. A pressure rise may be asymptomatic; a normal-feeling eye does not replace scheduled measurement. Increasing pain, redness, photophobia, discharge, or vision loss after an intraocular procedure requires prompt triage.

AREDS2 is not a general multivitamin and does not prevent every form of AMD. Confirm the exact formula and route smoking history to the clinician because beta-carotene-containing older formulations are inappropriate for current or former smokers. Copper is included in the AREDS formulations to reduce the risk of copper-deficiency anemia associated with high zinc intake. Patients should not double doses or replace prescribed treatment with supplements. The licensed clinician determines whether the patient's AMD category is one for which the evidence supports supplementation and reconciles interactions or duplicate ingredients.